Recent Publications from Our Center
Obi ON, Baughman RP. (2022). “Sarcoidosis ”. Book Chapter In Sam M. Janes (Ed.) Encyclopedia of Respiratory Medicine ,https://doi.org/10.1016/B978-0-12-801238-3.11660-5 .
Obi ON, Marcu CB, Sayers R, Sankhyan P, Tijani SM, Begelman K. (2022). “Imaging in Sarcoidosis – Lung, Cardiac, Neuroimaging and Others”. Chapter 10, pp 195-282; Book Chapter In: A Clinical Manual of Sarcoidosis . Editors Vikas Pathak and Shambhu Aryal . Copyright © 2022 Nova Science Publishers, Inc. ISBN: 978-1-68507-681-8(ebook). Published online March 2022.
Obi ON, Lower EE, Baughman RP. (2024). “Role of Corticosteroids and Anti-Inflammatory Therapy in the Treatment of Cardiac Sarcoidosis ”. Book Chapter In: Cardiac Sarcoidosis :
Obi ON, Alqalyoobi S, Maddipati V, Lower EE, Baughman RP. Fibrotic Patterns in Stage 4 Pulmonary Sarcoidosis: Impact on Pulmonary Function and Survival . Chest. 2024 Apr;165(4):892-907 . doi: 10.1016/j.chest.2023.10.021. Epub 2023 Oct 23. PMID: 37879560.
Wambui D, Kearney G, O’Brien K, Iverson G, Obi ON. Sarcoidosis Mortality in North Carolina: Role of Region, Race, and Other Sociodemographic Variables . North Carolina Medical Journal . 2024;85(4). doi:10.18043/001c.118578 .
Obi ON, Baughman RP, Crouser ED, Julian MW,Locke LW et al. Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis . Original Research. ERJ Open Research Jan 2024, 00536-2024; DOI: 10.1183/23120541.00536-2024.
Alqalyoobi S, Little BB, Oldham JM, Obi ON. The prognostic value of gastroesophageal reflux disorder in interstitial lung disease related hospitalizations . Respir Res. 2023 Mar 30;24(1):97. doi: 10.1186/s12931-023-02407-4 . PMID: 36998050; PMCID: PMC10061884.
Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. Chest. 2023 Apr;163(4):881-890 . doi: 10.1016/j.chest.2022.10.037. Epub 2022 Nov 8. PMID: 36356657; PMCID: PMC10258437.
Obi ON. Pulmonary Sarcoidosis: Beyond Restriction and Forced Vital Capacity . Ann Am Thorac Soc. 2023 Jan;20(1):24-26 . doi: 10.1513/AnnalsATS.202208-731ED. PMID: 36584989.
Zhou Y, Jeny F, Vucinic V, Talwar D, Obi ON, Judson MA, Strambu I, Bhattacharyya P, Valeyre D, Bickett AN, Lower EE, Baughman RP. Sarcoidosis Diagnostic Score (SDS) system: Impact of race, sex, organ involvement and duration of symptoms prior to diagnosis . Original Research. Respir Med Res. 2024 Jul 6;86:101127. doi: 10.1016/j.resmer.2024.101127. Epub ahead of print. PMID: 39084188.
Jeny F, Vucinic V, Zhou Y, Valeyre D, Bhattacharyya P, Bickett AN, Judson MA, Obi ON, Denis JE, Talwar D, Strambu I, Lower EE, Baughman RP. Validation of the Sarcoidosis Diagnostic Score (SDS) in a Multicontinental Study . Ann Am Thorac Soc. 2023 Mar;20(3):371-380. doi: 10.1513/AnnalsATS.202206-529OC. PMID: 36322428.
Alqalyoobi S, Liao SY, Qureshi W, Obi ON. National Temporal Trends in Hospitalization and Inpatient Mortality in Patients with Pulmonary Sarcoidosis in the United States between 2007 – 2018 . 2022 Jan;161(1):152-168. doi: 10.1016/j.chest.2021.07.2166. Epub 2021 Aug 5. PMID: 34364869 .
Obi ON, Judson MA, Birring SS, Wells AU, Lower EE, Baughman RP. Assessment of Dyspnea in Sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI) . Respiratory Medicine 2021 May 4:106436. doi: 10.1016/j.rmed.2021.106436 . Epub ahead of print. PMID: 33992496.
Zhou Y, Gerke A, Lower EE, Vizel A, Talwar D, Strambu I, Francesqui J, Sellares J, Sawahata M, Obi ON, Nagai S, Tanizawa K, Judson M, Jeny F, Valeyre D, Cunha Castro MD, Pereira C, Balter M, Baughman RP. The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study. Respiratory Medicine 2021 August; 187:106564. https://doi.org/10.1016/ j.rmed.2021.106564 . Epub ahead of print. PMID: 34391118.
Obi ON, Baughman RP. Mixed Obstructive and Restrictive Ventilatory Defects in Sarcoidosis: A New Phenotype? Editorial for: Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features. Chest. 2020 Nov; 158(5): 1818-1819. PMID:33160525 .
Wambui DW, Obi ON, Kearney GD. Association between Obesity and Risk of Sarcoidosis: A systematic Review and Meta-Analysis . American Journal of Internal Medicine. Special Issue: Occupational and Environmental Lung Diseases: The Emerging Global Health Threats. Am J Int Med 2020; 8(5): 237-245. DOI: 10.11648/j.ajim.20200805.18 .
Kearney GD, Obi ON, Maddipati V, Mohan A, Malur A, Carter, CJ, Thomassen MJ. Sarcoidosis deaths in the United States: 1999 – 2016 . Respir Med. 2019 Mar; 149:30-35. DOI: 10.1016/j.rmed.2018.11.010 . PMID: 30471894.
Obi ON, Voortman M. Sarcoidosis: now and into the future. Curr Opin Pulm Med. 2022 Sep 1;28(5):448-450 . doi: 10.1097/MCP.0000000000000899. PMID: 35938202.
Obi ON, Sharp M, Harper L. Progress for all: Addressing Disparities in Sarcoidosis . Curr Opin Pulm Med. 2024 Jul 11. doi: 10.1097/MCP.0000000000001104. Epub ahead of print. PMID: 38989780.
Obi ON. Diversity and disparity in the treatment and care of sarcoidosis . Curr Opin Pulm Med. 2023 Jul 11. doi: 10.1097/MCP.0000000000000994 . Epub ahead of print. PMID: 37431305.
Moor CC, Obi ON, Kahlmann V, Buschulte K, Wijsenbeek M. Quality of Life in Sarcoidosis . Review Paper. Journal of Autoimmunity, 2023, 103123, ISSN 0896-8411 . https://doi.org/10.1016/j.jaut.2023.103123 .
Obi ON. Health-Related Quality of Life in Sarcoidosis . Semin Respir Crit Care Med. 2020 Oct;41(5):716-732. doi: 10.1055/s-0040-1710080 . Epub 2020 Jun 24. PMID: 32583381.
Saketkoo LA, Obi ON, Patterson KC, Russell AM. Ageing with Interstitial lung disease: preserving health and well-being. Curr Opin Pulm Med. 2022 Jul 1;28(4):321-336 . doi: 10.1097/MCP.0000000000000880. PMID: 35749798.
Obi ON, Saketkoo LA, Maier LA, Baughman RP. Developmental drugs for sarcoidosis . J Autoimmunity 2024 Mar 28:103179 . doi: 10.1016/j.jaut.2024.103179. Epub ahead of print. PMID: 38548579.
Obi ON. Anti-inflammatory Therapy for Sarcoidosis . Clin Chest Med. 2024 Mar;45(1):131-157 . doi: 10.1016/j.ccm.2023.08.010. Epub 2023 Sep 9. PMID: 38245362.
Obi ON, Saketkoo LA, Russell AM, Baughman RP. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Front Med (Lausanne). 2022 Oct 12;9:991783. doi:10.3389/fmed.2022.991783 . PMID: 36314034; PMCID: PMC9596775
Obi ON, Lower EE, Baughman RP. Controversies in the Treatment of Cardiac Sarcoidosis . Review paper. Sarcoidosis, Vasc Diffuse Lung Dis [Internet]. 2022 Jun. 29; 39 (2); e2022015.
Obi ON, Lower EE, Baughman RP. Biologic and Advanced Immunomodulating Therapeutic Options for Sarcoidosis: A Clinical Update . Expert Review of Clinical Pharmacology 2021 Feb;14(2):179-210. doi: 10.1080/17512433.2021.1878024 . Epub 2021 Jan 31. PMID: 33487042.
Soliman E, Bhalla S, Elhassanny AEM, Malur A, Ogburn D, Leffler N, Malur AG, Thomassen MJ. Myeloid ABCG1 Deficiency Enhances Apoptosis and Initiates Efferocytosis in Bronchoalveolar Lavage Cells of Murine Multi-Walled Carbon Nanotube-Induced Granuloma Model. Int J Mol Sci. 2021 Dec 21;23(1):47 . doi: 10.3390/ijms23010047. PMID: 35008476; PMCID: PMC8744594.
Ogburn D, Bhalla S, Leffler N, Mohan A, Malur A, Malur AG, McPeek M, Barna BP, Thomassen MJ. The M2a Macrophage Phenotype Accompanies Pulmonary Granuloma Resolution in Mmp12 Knock-Out Mice Instilled with Multiwall Carbon Nanotubes. Int J Mol Sci. 2021 Oct 13;22(20):11019. doi: 10.3390/ijms222011019. PMID: 34681679; PMCID: PMC8537143.
Barna BP, Malur A, Thomassen MJ. Studies in a Murine Granuloma Model of Instilled Carbon Nanotubes: Relevance to Sarcoidosis. Int J Mol Sci. 2021 Apr 2;22(7):3705. doi: 10.3390/ijms22073705. PMID: 33918196; PMCID: PMC8038141.
Mohan A, Neequaye N, Malur A, Soliman E, McPeek M, Leffler N, Ogburn D, Tokarz DA, Knudson W, Gharib SA, Schnapp LM, Barna BP, Thomassen MJ. Matrix Metalloproteinase-12 Is Required for Granuloma Progression. Front Immunol. 2020 Sep 18;11:553949. doi: 10.3389/fimmu.2020.553949. PMID: 33072094; PMCID: PMC7531023.
Soliman E, Elhassanny AEM, Malur A, McPeek M, Bell A, Leffler N, Van Dross R, Jones JL, Malur AG, Thomassen MJ. Impaired mitochondrial function of alveolar macrophages in carbon nanotube-induced chronic pulmonary granulomatous disease. Toxicology. 2020 Dec 1;445:152598. doi: 10.1016/j.tox.2020.152598. Epub 2020 Sep 22. PMID: 32976959; PMCID: PMC7606835.
Sanderford V, Barna BP, Barrington RA, Malur A, Mohan A, Leffler N, Soliman E, Thomassen MJ. PPARγ Deficiency in Carbon Nanotube-elicited Granulomatous Inflammation Promotes a Th17 Response to a Microbial Antigen. J Nanomed Nanotechnol. 2020;11(1):541. doi: 10.35248/2157-7439.20.11.541. Epub 2020 Feb 18. PMID: 32405439; PMCID: PMC7219023.
Malur A, Mohan A, Barrington RA, Leffler N, Malur A, Muller-Borer B, Murray G, Kew K, Zhou C, Russell J, Jones JL, Wingard CJ, Barna BP, Thomassen MJ. Peroxisome Proliferator-activated Receptor-γ Deficiency Exacerbates Fibrotic Response to Mycobacteria Peptide in Murine Sarcoidosis Model. Am J Respir Cell Mol Biol. 2019 Aug;61(2):198-208. doi: 10.1165/rcmb.2018-0346OC. PMID: 30741559; PMCID: PMC6670028.
McPeek M, Malur A, Tokarz DA, Murray G, Barna BP, Thomassen MJ. PPAR-gamma pathways attenuate pulmonary granuloma formation in a carbon nanotube induced murine model of sarcoidosis. Biochem Biophys Res Commun. 2018 Sep 5;503(2):684-690. doi: 10.1016/j.bbrc.2018.06.061. Epub 2018 Jun 15. PMID: 29908181; PMCID: PMC6432932.
Mohan A, Malur A, McPeek M, Barna BP, Schnapp LM, Thomassen MJ, Gharib SA. Transcriptional survey of alveolar macrophages in a murine model of chronic granulomatous inflammation reveals common themes with human sarcoidosis. Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L617-L625. doi: 10.1152/ajplung.00289.2017. Epub 2017 Dec 6. PMID: 29212802; PMCID: PMC5966779.
Gharib SA, Malur A, Huizar I, Barna BP, Kavuru MS, Schnapp LM, Thomassen MJ. Sarcoidosis activates diverse transcriptional programs in bronchoalveolar lavage cells. Respir Res. 2016 Jul 26;17(1):93. doi: 10.1186/s12931-016-0411-y. PMID: 27460362; PMCID: PMC4962428.
Malur A, Barna BP, Patel J, McPeek M, Wingard CJ, Dobbs L, Thomassen MJ. Exposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary Disease. J Nanomed Nanotechnol. 2015 Dec;6(6):340. doi: 10.4172/2157-7439.1000340. Epub 2015 Dec 27. PMID: 27019768; PMCID: PMC4807875.
Barna BP, McPeek M, Malur A, Fessler MB, Wingard CJ, Dobbs L, Verbanac KM, Bowling M, Judson MA, Thomassen MJ. Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease. Am J Respir Cell Mol Biol. 2016 Jun;54(6):865-71 . doi: 10.1165/rcmb.2015-0332OC. PMID: 26641802; PMCID: PMC4942222.
Barna BP, Huizar I, Malur A, McPeek M, Marshall I, Jacob M, Dobbs L, Kavuru MS, Thomassen MJ. Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation. Int J Mol Sci. 2013 Dec 6;14(12):23858-71. doi: 10.3390/ijms141223858. PMID: 24322444; PMCID: PMC3876082.
Huizar I, Malur A, Midgette YA, Kukoly C, Chen P, Ke PC, Podila R, Rao AM, Wingard CJ, Dobbs L, Barna BP, Kavuru MS, Thomassen MJ. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes . Am J Respir Cell Mol Biol. 2011 Oct;45(4):858-66. doi: 10.1165/rcmb.2010-0401OC. Epub 2011 Mar 11. PMID: 21398620; PMCID: PMC5460893.
Back to top 